115 – Labeling Changes & Post-Market Commitments (S8E10)

This episode explores how drug labels evolve after a medication has been approved, including safety updates, new indications, and the addition of black box warnings. We discuss the regulatory commitments that companies must meet, such as post-market studies and REMS (Risk Evaluation and Mitigation Strategies) requirements. Examples of communicating with healthcare professionals and examples are shared.

The conversation highlights communication strategies for informing healthcare providers and patients about these label changes. Real-world examples, such as label changes for opioids, biologics, and high-risk drugs, are used to illustrate the practical implications of these updates. The episode emphasizes the dynamic nature of drug labeling and the continuous process of ensuring that it reflects the most up-to-date safety and efficacy information.